Diabetic nephropathy is a complication of diabetes characterised by damage to the kidneys filtering system. It hampers the ability of kidneys to remove waste products and extra fluid from body. Some of the most common symptoms of diabetic nephropathy include high blood pressure, fatigue, anorexia, headache, skin dryness, and swelling of limbs. The most common risk factors of diabetic nephropathy include diabetes, high blood sugar, high blood pressure, smoking, and heredity. Approximately 40% of people with diabetes eventually develop kidney disease. According to an estimate approximately 180,000 people are suffering from kidney failure caused by diabetes.
The main growth drivers for the therapeutic pipeline of diabetic nephropathy are increasing investment in research and development of new drugs for the disease, rising prevalence of diabetes and obesity, elevated awareness about diabetes and kidney-related disorders. According to International Diabetes Federation the prevalence of diabetes worldwide is 415 million people globally and it is estimated to reach to 642 million people by 2040.
In recent years, many big pharmaceutical companies have invested significant amount of capital on the research and development of drugs for nephropathy. In March 2017, Ironwood Pharmaceuticals, Inc. announced that it will initiate a Phase II clinical trial investigating IW-1973 in diabetic nephropathy. IW-1973 is an investigational soluble guanylate cyclase (sGC) stimulator which plays an important role in regulating diverse physiological processes such as blood flow, inflammation, fibrosis, and metabolism. The company expects that IW-1973 could generate annual peak sales of more than $5.0 billion, globally.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/diabetic-nephropathy-therapeutics-pipeline-analysis/toc-sample
The major market players having drugs in pipeline for diabetic nephropathy includes Eli Lilly and Company, Reata Pharmaceuticals, Inc., Abbott Laboratories, AbbVie Inc., Bayer AG, Novartis AG, Pfizer, Inc., Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Co., Ltd., ChemoCentryx Inc., Mallinckrodt Pharmaceuticals and GenKyoTex S.A.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)